Skip to Content

Chiesi Is Top Italian Pharmaceutical Group for Investment In Research

Parma, Italy, 19th November 2009 – The Chiesi Group, which is based in Parma, ranks top among Italian investors in Research and Development within the pharmaceutical sector, putting it in eighth place in the ranking of the biggest national groups from all sectors, and in thirteenth place among European pharmaceutical multinationals. These results are reported in the “2009 EU R&D Industrial Investment Scoreboard”, developed by the European Commission’s Joint Research Centre. The document was drawn up on the basis of the balance sheets submitted to the JRC by businesses, although it does not however represent all existing companies.

The Chiesi Group, with an investment of 107.8 million Euro (+16.7% on 2007), follows some of the most important national companies, such as FIAT, Finmeccanica, Telecom Italia and Pirelli, whereas in the pharmaceutical sector the group falls close behind key groups such as Sanofi-Aventis, GlaxoSmithKline, Astrazeneca and Boehringer Ingelheim in Europe.

“The Chiesi Group has grown over the past twenty years thanks to a careful investment policy in research and development for new drugs, which has generated products such as Curosurf®, world leader in the treatment of respiratory distress syndrome in premature infants, and Foster®, indicated for the treatment of asthma” comments Alberto Chiesi, Chairman and Managing Director of the Group. “For a number of years we have dedicated a significant proportion of our turnover to research and development as we believe that innovation is the best resource to compete with in an increasingly competitive sector, such as that of pharmaceuticals”, he sums up.

Moreover, the 2009 Scoreboard also highlights the fact that the increase in investments made by businesses based in the European Union, totalling 8.1%, is in excess of that made by US (+5.7%) and Japanese businesses (+4.4%) for the second consecutive year. The pharmaceutical and biotechnology sector has strengthened its leadership among the largest R&D investors at global level both in the US and Europe (EU + Switzerland).
Chiesi profile
Founded in 1935 in Parma, the Chiesi Group generated a turnover of 749 million Euro in 2008, which was up by 14.1% on 2007, and almost three times the average European growth rate. The Group, which mainly operates in the respiratory and rare disease fields, now boasts 23 affiliates worldwide and its drugs, produced at its plants in Parma, Blois (France) and Santana de Parnaiba (Brazil), are currently present in over 50 countries.
In 2008 investments in R&D totalled 107.8 million Euro, representing 14.5% of the turnover, almost achieving 15%, the objective the company has set itself, and one which it intends to maintain over the next few years. In addition to the three research laboratories in Parma, Paris and Rockville (USA), there is now a fourth lab in Chippenham (UK) which opened in 2008 and is now fully operative, and that aims to develop innovative solutions for pressurised aerosol technology.
At the end of 2008 the Chiesi Group employed 3,324 members of staff, over 300 of which are researchers and around 600 working at the Italian, French and Brazilian production sites.


For further information:
Chiesi Farmaceutici S.p.A.
Massimo Zaninelli
Corporate Communication Manager
Tel: 0521-279084

Press Office
Tel: 02-20241357
Cristina Depaoli, cell. 334 6068948, e-mail:

Posted: November 2009